Related references
Note: Only part of the references are listed.Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
K. Chatzidionysiou et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2013)
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach
Susanne Schmitz et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0
Juan J. Gomez-Reino et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
Vibeke Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom
Patricia Guyot et al.
JOURNAL OF RHEUMATOLOGY (2012)
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
Vibeke Strand et al.
RHEUMATOLOGY (2012)
Overview of safety of non-biologic and biologic DMARDs
Eric M. Ruderman
RHEUMATOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
Carine Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis
Robert Launois et al.
JOURNAL OF RHEUMATOLOGY (2011)
Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
Emily Beth Devine et al.
PHARMACOTHERAPY (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective
John L. Moran et al.
CRITICAL CARE (2010)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons
Jeroen P. Jansen et al.
VALUE IN HEALTH (2008)
Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis
Young Ho Lee et al.
RHEUMATOLOGY INTERNATIONAL (2008)
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial
R. Westhovens et al.
RHEUMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Work disability in rheumatoid arthritis is predicted by physical and psychological health status:: a 7-year study from the Oslo RA register
S Odegård et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normative values for the health assessment questionnaire disability index -: Benchmarking disability in the general population
E Krishnan et al.
ARTHRITIS AND RHEUMATISM (2004)
Drug therapy - Therapeutic strategies for rheumatoid arthritis
JR O'Dell
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Combination of direct and indirect evidence in mixed treatment comparisons
G Lu et al.
STATISTICS IN MEDICINE (2004)
Share Paper
